Neoplasm of uncertain behavior of other and unspecified sites

Code-level instructions

Excludes 1

neurofibromatosis (nonmalignant) (Q85.0-)

D37-D48 · Inherited instructions

Excludes 1

neoplasms of unspecified behavior (D49.-)

More specific codes

Claims & coverage

When ICD-10-CM is required

For US diagnosis claims covered by HIPAA, ICD-10-CM is required from October 1, 2015.

Use the service date for outpatient/professional claims and the discharge date for hospital inpatient claims. Earlier encounters use ICD-9-CM; each individual code must also be valid for the applicable date.

Official coding guidelines → · CMS ↗

First observed · 2015-10-01

Code history

No recorded change since first observation

ChangedUnchanged

FY2016

Effective from 2015-10-01

First observed

Neoplasm of uncertain behavior of other and unspecified sites

Category — select a more specific code

CDC/NCHS · FY2016

All editions (19)

All editions	Effective from	Code history
FY2016	2015-10-01	First observed
FY2017	2016-10-01	No tabular change
FY2018	2017-10-01	No tabular change
FY2019	2018-10-01	No tabular change
FY2020	2019-10-01	No tabular change
FY2020 · April	2020-04-01	No tabular change
FY2021	2020-10-01	No tabular change
FY2021 · 01-01	2021-01-01	No tabular change
FY2022	2021-10-01	No tabular change
FY2022 · 04-01	2022-04-01	No tabular change
FY2023	2022-10-01	No tabular change
FY2023 · 04-01	2023-04-01	No tabular change
FY2024	2023-10-01	No tabular change
FY2024 · 04-01	2024-04-01	No tabular change
FY2025	2024-10-01	No tabular change
FY2025 · 04-01	2025-04-01	No tabular change
FY2026	2025-10-01	No tabular change
FY2026 · April	2026-04-01	No tabular change
FY2027	2026-10-01	No tabular change

Code-level instructions

Excludes 1

neurofibromatosis (nonmalignant) (Q85.0-)

Inherited instructions

Chapters 2 · Neoplasms (C00-D49)

Note

Functional activity
All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
Morphology [Histology]
Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
Primary malignant neoplasms overlapping site boundaries
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
Malignant neoplasm of ectopic tissue
Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).

D37-D48 · Neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes (D37-D48)

Excludes 1

neoplasms of unspecified behavior (D49.-)

Note

Categories D37-D44, and D48 classify by site neoplasms of uncertain behavior, i.e., histologic confirmation whether the neoplasm is malignant or benign cannot be made.

More specific codes

Related codes

Official titles and instructions are preserved in their source language. Official sources ↗

References from other codes (3)

D49 · Neoplasms of unspecified behavior

Excludes 2 · neoplasms of uncertain behavior (D37-D44, D48)

O99.8 · Other specified diseases and conditions complicating pregnancy, childbirth and the puerperium

Inclusion terms · Conditions in D00-D48, H00-H95, M00-N99, and Q00-Q99

sections/D37-D48 · Neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes (D37-D48)

Note · Categories D37-D44, and D48 classify by site neoplasms of uncertain behavior, i.e., histologic confirmation whether the neoplasm is malignant or benign cannot be made.